CPT code 33361 denotes transcatheter aortic valve implantation/replacement (TAVI/TAVR) performed percutaneously via the femoral artery to deliver an aortic valve prosthesis through a catheter. This minimally invasive alternative to open surgical aortic valve replacement has become an important option for patients with symptomatic aortic stenosis across risk profiles, driving significant utilization and payer attention nationally.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the clinical context for percutaneous femoral TAVR, a summary of the service setting and typical care pathway, and a synthesis of what payers commonly consider when covering this service. The publication outlines where benchmarking data and policy updates typically appear — including utilization patterns, site-of-service considerations, and common documentation elements — and highlights areas where coding specificity affects claims and reporting.

This overview is intended for health policy analysts, revenue cycle leaders, and clinicians who need a clear, national-level briefing on CPT code 33361, its clinical role, and the payer landscape. Data not available in the input is noted where applicable; the focus remains on clinical description, service setting, and the primary payers relevant to national coverage and billing practice.